{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:03:46Z","timestamp":1782533026188,"version":"3.54.5"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":419,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Colton Scholarship"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In clinical trials, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved symptoms in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). We aimed to share our real-world experience with the efficacy and safety of mavacamten in this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This retrospective, single-centre study included patients with symptomatic oHCM from March 2023 to November 2023. Inclusion criteria were oHCM, age &amp;gt;18 years, significant LVOTO (gradient &amp;gt;50 mmHg at rest or with Valsalva), New York Heart Association (NYHA) class \u2265II despite maximally tolerated medical therapy, and left ventricular ejection fraction (LVEF) &amp;gt;55%. Patients were evaluated by echocardiography, NYHA class, electrocardiography and Holter monitor on each monthly visit for 3 months. A total of 31 patients were included in this study. The mean (SD) age was 58 (16.5) years, and 14 (45%) were female. Mean provoked left ventricular outflow tract gradient (LVOTG) reduced by \u221249.4 mmHg (P &amp;lt; 0.001) at 4 weeks, \u221259.2 mmHg (P &amp;lt; 0.001) at 8 weeks, and \u221260.8 mmHg (P &amp;lt; 0.001) at 12 weeks. Twenty-six of the 31 patients (83.8%) achieved an LVOTG \u226430 mmHg at Week 12. No major side effects were reported. Sixty-seven percent experienced \u22652 NYHA class improvements, LVEF remained above 55% and no dose titration was made.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our real-world experience aligns with established mavacamten trial outcomes. Continuous vigilance and longitudinal investigations are needed to further assess potential long-term impacts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14882","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:01:49Z","timestamp":1723554109000},"page":"672-676","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mavacamten in Real-Life Practice: Initial Experience at a Hypertrophic Cardiomyopathy Centre"],"prefix":"10.1093","volume":"12","author":[{"given":"Zaid","family":"Abood","sequence":"first","affiliation":[{"name":"Aurora Cardiovascular and Thoracic Services, Aurora Sinai\/Aurora St. Luke\u2019s Medical Centers, Aurora Health Care , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Fuad","family":"Jan","sequence":"additional","affiliation":[{"name":"Aurora Cardiovascular and Thoracic Services, Aurora Sinai\/Aurora St. Luke\u2019s Medical Centers, Aurora Health Care , Milwaukee, Wisconsin ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee Clinical Campus , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muddasir","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Aurora Cardiovascular and Thoracic Services, Aurora Sinai\/Aurora St. Luke\u2019s Medical Centers, Aurora Health Care , Milwaukee, Wisconsin ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee Clinical Campus , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie","family":"Kroboth","sequence":"additional","affiliation":[{"name":"Academic Affairs, Cardiovascular Research, Aurora Sinai\/Aurora St. Luke\u2019s Medical Centers, Aurora Health Care , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Sanders","sequence":"additional","affiliation":[{"name":"Aurora Cardiovascular and Thoracic Services, Aurora Sinai\/Aurora St. Luke\u2019s Medical Centers, Aurora Health Care , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenzie","family":"Schweitzer","sequence":"additional","affiliation":[{"name":"Aurora Cardiovascular and Thoracic Services, Aurora Sinai\/Aurora St. Luke\u2019s Medical Centers, Aurora Health Care , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Misicka","sequence":"additional","affiliation":[{"name":"Aurora Cardiovascular and Thoracic Services, Aurora Sinai\/Aurora St. Luke\u2019s Medical Centers, Aurora Health Care , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Ollerman","sequence":"additional","affiliation":[{"name":"Aurora Cardiovascular and Thoracic Services, Aurora Sinai\/Aurora St. Luke\u2019s Medical Centers, Aurora Health Care , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad","family":"Jahangir","sequence":"additional","affiliation":[{"name":"Aurora Cardiovascular and Thoracic Services, Aurora Sinai\/Aurora St. Luke\u2019s Medical Centers, Aurora Health Care , Milwaukee, Wisconsin ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee Clinical Campus , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Galazka","sequence":"additional","affiliation":[{"name":"Aurora Cardiovascular and Thoracic Services, Aurora Sinai\/Aurora St. Luke\u2019s Medical Centers, Aurora Health Care , Milwaukee, Wisconsin ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee Clinical Campus , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Jamil","family":"Tajik","sequence":"additional","affiliation":[{"name":"Aurora Cardiovascular and Thoracic Services, Aurora Sinai\/Aurora St. Luke\u2019s Medical Centers, Aurora Health Care , Milwaukee, Wisconsin ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee Clinical Campus , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"2026012113064606400_ehf214882-bib-0001","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026012113064606400_ehf214882-bib-0002","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/circulationaha.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"2026012113064606400_ehf214882-bib-0003","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/ehjci\/jex215","article-title":"Marked respiratory-related fluctuations in left ventricular outflow tract gradients in hypertrophic obstructive cardiomyopathy: an observational study","volume":"19","author":"Jain","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012113064606400_ehf214882-bib-0004","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","article-title":"Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur Heart J"},{"key":"2026012113064606400_ehf214882-bib-0005","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0033-0620(68)90011-x","article-title":"Chronic beta adrenergic receptor blockade in the treatment of idiopathic hypertrophic subaortic stenosis","volume":"11","author":"Cohen","year":"1968","journal-title":"Prog Cardiovasc Dis"},{"key":"2026012113064606400_ehf214882-bib-0006","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1161\/cir.0000000000000937","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"2026012113064606400_ehf214882-bib-0007","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.amjcard.2022.06.007","article-title":"Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC Expert Panel","volume":"180","author":"Maron","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026012113064606400_ehf214882-bib-0008","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"2026012113064606400_ehf214882-bib-0009","doi-asserted-by":"publisher","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","article-title":"Mavacamten decreases maximal force and Ca(2+) sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy","volume":"320","author":"Awinda","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026012113064606400_ehf214882-bib-0010","volume-title":"FDA approves new drug to improve heart function in adults with rare heart condition (press release)","author":"US Food and Drug Administration"},{"key":"2026012113064606400_ehf214882-bib-0011","volume-title":"Full prescribing information (CAMZYOS)","author":"Bristol Myers Squibb"},{"key":"2026012113064606400_ehf214882-bib-0012","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s0140-6736(20)31792-x","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026012113064606400_ehf214882-bib-0013","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1001\/jamacardio.2022.5099","article-title":"Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the EXPLORER-HCM randomized trial","volume":"8","author":"Wheeler","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026012113064606400_ehf214882-bib-0014","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/m18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026012113064606400_ehf214882-bib-0015","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026012113064606400_ehf214882-bib-0016","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7293","article-title":"Association of septal myectomy with quality of life in patients with left ventricular outflow tract obstruction from hypertrophic cardiomyopathy","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026012113064606400_ehf214882-bib-0017","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/0735-1097(96)00038-1","article-title":"Hypertrophic obstructive cardiomyopathy: preoperative echocardiographic predictors of outcome after septal myectomy","volume":"27","author":"McCully","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"2026012113064606400_ehf214882-bib-0018","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.amjcard.2022.12.008","article-title":"Regional disparities in the use of septal reduction therapy and associated outcomes in the United States (from a real-world database)","volume":"191","author":"Ashraf","year":"2023","journal-title":"Am J Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/1\/672\/64513389\/eschf_12_1_672.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/1\/672\/64513389\/eschf_12_1_672.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:06:54Z","timestamp":1769018814000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/1\/672\/8261854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,13]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14882","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"2024-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}